Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Viewpoint
  • Published:

Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Blanke CD et al. (2006) Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate [abstract #9528]. J Clin Oncol 24: 526s

    Google Scholar 

  2. Demetri GD et al. (2007) NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5 (Suppl 2): S1–S29

    Article  Google Scholar 

  3. DeMatteo RP et al. (2007) Ballman and the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. In Proceedings of the 43rd ASCO Annual Meeting: 1–5 June 2007 Part I. J Clin Oncol 25 (June 20 Suppl):10079

    Google Scholar 

  4. DeMatteo RP et al. (2005) Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the US Intergroup Phase II trial ACOSOG Z9000 [abstract #9009]. J Clin Oncol 23:16S

    Article  Google Scholar 

  5. Blay JY et al. (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25: 1107–1113

    Article  CAS  Google Scholar 

  6. Rios M et al. (2007) French Sarcoma Group: interruption of imatinib (IM) in GIST patients with advanced disease after one year of treatment—updated results of the prospective French Sarcoma Group randomized phase III trial on long term survival. In Proceedings of the 43rd ASCO Annual Meeting: 1–5 June 2007 Part I. J Clin Oncol 25 (June 20 Suppl): 10079

    Google Scholar 

  7. Rutkowski P et al. (2006) Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 93: 304–311

    Article  Google Scholar 

  8. Wardelmann E et al. (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12: 1743–1749

    Article  CAS  Google Scholar 

  9. Miettinen M and Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23: 70–83

    Article  Google Scholar 

  10. Martin J et al. (2005) Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 23: 6190–6198

    Article  CAS  Google Scholar 

  11. Debiec-Rychter M et al. (2006) KIT mutations should guide dose selection for imatinib in patients with advanced gastrointestinal stromal tumors: results of mutation analysis in 377 patients entered into a randomized study. Eur J Cancer 42: 1093–1103

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author is a Consultant for Novartis and Pfizer and receives grant/research support from Novartis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hohenberger, P. Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?. Nat Rev Clin Oncol 5, 240–241 (2008). https://doi.org/10.1038/ncponc1091

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc1091

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing